RDB04383 - CSII-CMV-MCS-IRES2-Venus

Resource data sheet
Prev. | Lentiviral vector plasmid >

CSII-CMV-MCS-IRES2-Venus

Backbone vector of lentivirus construct driven by CMV promoter with Venus fluorescent protein marker.

Catalog number	RDB04383
Resource name	CSII-CMV-MCS-IRES2-Venus
Clone info.	Backbone vector of lentivirus construct driven by CMV promoter with Venus fluorescent protein marker. Commonly requested with pCMV-VSV-G-RSV-Rev (RDB04393) and pCAG-HIVgp (RDB04394). Please note that Zeo resistance marker is not included in the lentivirus produced from this vector.
Vector backbone	CSII-CMV-MCS (Plasmid)
Selectable markers	Amp^r (E. coli); Zeo^r (plasmid transfection of mammalian cells).
Gene/insert name	Aequorea victoria GFP cDNA
Originator	Miyoshi, Hiroyuki \|

Lentiviral plasmid list, maps and sequences information. [link]

Distribution information

Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe Dr. Hiroyuki Miyoshi (The Developer, the current address: Keio University) as the Developer. Dr. Miyoshi may request the RECIPIENT to report on progress and/or results obtained through the use of the BIOLOGICAL RESOURCE.

Additional terms and conditions for distribution Regarding the use of Venus, a written approval of Dr. Atsusi Miyawaki is required.

Ordering Please visit Ordering instruction.
Order form [Credit Card Payment] [Bank Transfer or Check Payment]
Exclusive MTA [Word]
Approval form [Word] by Dr. Atsushi Miyawaki

Remarks ((Remarks)) Remember that you will be working with samples containing infectious virus.
Please contact us. We will provide you with appropriate documents.

Distribution information (domestic users) [open/close]

Terms and conditions for distribution	The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose. The RECIPIENT agrees to expressly describe Dr. Hiroyuki Miyoshi (The Developer, the current address: Keio University) as the Developer. Dr. Miyoshi may request the RECIPIENT to report on progress and/or results obtained through the use of the BIOLOGICAL RESOURCE.
Additional terms and conditions for distribution	Regarding the use of Venus, a written approval of Dr. Atsusi Miyawaki is required.
Ordering	Please visit Ordering instruction. Order form [Credit Card Payment] [Bank Transfer or Check Payment] Exclusive MTA [Word] Approval form [Word] by Dr. Atsushi Miyawaki
Remarks	((Remarks)) Remember that you will be working with samples containing infectious virus. Please contact us. We will provide you with appropriate documents.

提供条件	本件研究材料は、非営利機関の非営利学術研究に限って提供する。本件研究材料を利用した研究結果等を発表する際は、本件研究材料が三好浩之（現職：慶應義塾大学）により開発されたことを明示する。三好浩之は、利用の状況及び成果等について利用者に報告を求めることができる。
付加的提供条件	Venus の使用について、宮脇敦史博士の書面による提供承諾を必要とする。
提供依頼	手続きの詳細は、「レンチウイルスベクターの提供申し込み」をご覧ください。提供依頼書 [Word] 専用の研究材料等提供同意書[Word] 遺伝子組換え生物の受入れ確認書 [Word] 宮脇敦史博士による提供承諾書 [Word]
備考	【使用上の注意】このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB04383	CSII-CMV-MCS-IRES2-Venus	DNA solution

Ordering instruction of plasmids [in Japanese] [in English]

References and tips

Electronic file

Electronic file	Sequence RDB04383z.seq from Depositor
Electronic file	PDF (map, protocol and/or remarks) RDB04383.pdf from Depositor

Sequence information

RIKEN BRC has sequenced portions of this material for quality test. Primers and the results are shown below.

Data are summerized on test sheet below.

Test sheet	RDB04383_A2Kmp1.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: IRES-F	RDB04383_A2Kma.seq
>04383_04383_A2Km_IRES-R_E01_13.ab1 1 GCTAGCGGCT TCGGCAGTAC GTTAGGGGGG GGGGAGGGAG AGGGGCGGAT CCGCGGCCGC 61 TGCAGAATTC TCGAGACCGG TAGCGCTAGC GGATCTGACG GTTCACTAAA CCAGCTCTGC 121 TTATATAGAC CTCCCACCGT ACACGCCTAC CGCCCATTTG CGTCAATGGG GCGGAGTTGT 181 TACGACATTT TGGAAAGTCC CGTTGATTTT GGTGCCAAAA CAAACTCCCA TTGACGTCAA 241 TGGGGTGGAG ACTTGGAAAT CCCCGTGAGT CAAACCGCTA TCCACGCCCA TTGATGTACT 301 GCCAAAACCG CATCACCATG GTAATAGCGA TGACTAATAC GTAGATGTAC TGCCAAGTAG 361 GAAAGTCCCA TAAGGTCATG TACTGGGCAT AATGCCAGGC GGGCCATTTA CCGTCATTGA 421 CGTCAATAGG GGGCGTACTT GGCATATGAT ACACTTGATG TACTGCCAAG TGGGCAGTTT 481 ACCGTAAATA CTCCACCCAT TGACGTCAAT GGAAAGTCCC TATTGGCGTT ACTATGGGAA 541 CATACGTCAT TATTGACGTC AATGGGCGGG GGTCGTTGGG CGGTCAGCCA GGCGGGCCAT 601 TTACCGTAAG TTATGTAACG CGGAACTCCA TATATGGGCT ATGAACTAAT GACCCCGTAA 661 TTGATTACTA TTAATCGAAT TAATTCAAAG TGAATTTCTG CTGTCCCTGT AATAAACCCG 721 AAAATTTTGA ATTTTTGTAA TTTGTTTTTG TAATTCTTTA GTTTGTATGT CTGTTGCTAT 781 TATGTCTACT ATTCTTTCCC CTGCACTGTA CCCCCCAATC CCCCCTTTTC TTTTAAAATT 841 GTGGATGAAT ACTGCCATTT GTAGATCCGT TCACTAATCG AATGGATCTG TCTCTGTCTC 901 TCTCTCCACC TTCTTCTTCT ATTCCTTCGG GCCTGTCGGG TCCCCTCGGG GTTGGGAGGT 961 GGGTCTGAAA CGATAATGGT GAATATCCCT GCCTAACTCT ATTCACTATA GAAAGTACAG 1021 CAAAAAACTA TTCTTAAACC TACCCAAGCC TCCTACTATC ATTTATGAAT AATTTTTATA 1081 TACCACAGCC CAATTTGTTA TGGTAAATCA ATCACAAACT TTGCCCAATT TATCTAAATT 1141 CCAATAATTC TTGGTTTCCA ATC //
Primer: IRES-R	RDB04383_A2Kmb.seq
>04383_04383_A2Km_IRES-F_D01_10.ab1 1 GAGGCGTTAA TGTGTTTAGT CGAGGTTAAA AACGTCTAGG CCCCCCGAAC CACGGGGACG 61 TGGTTTTCCT TTGAAAAACA CGATGATAAT ATGGCCACAA CCATGGTGAG CAAGGGCGAG 121 GAGCTGTTCA CCGGGGTGGT GCCCATCCTG GTCGAGCTGG ACGGCGACGT AAACGGCCAC 181 AAGTTCAGCG TGTCCGGCGA GGGCGAGGGC GATGCCACCT ACGGCAAGCT GACCCTGAAG 241 CTGATCTGCA CCACCGGCAA GCTGCCCGTG CCCTGGCCCA CCCTCGTGAC CACCCTGGGC 301 TACGGCCTGC AGTGCTTCGC CCGCTACCCC GACCACATGA AGCAGCACGA CTTCTTCAAG 361 TCCGCCATGC CCGAAGGCTA CGTCCAGGAG CGCACCATCT TCTTCAAGGA CGACGGCAAC 421 TACAAGACCC GCGCCGAGGT GAAGTTCGAG GGCGACACCC TGGTGAACCG CATCGAGCTG 481 AAGGGCATCG ACTTCAAGGA GGACGGCAAC ATCCTGGGGC ACAAGCTGGA GTACAACTAC 541 AACAGCCACA ACGTCTATAT CACCGCCGAC AAGCAGAAGA ACGGCATCAA GGCCAACTTC 601 AAGATCCGCC ACAACATCGA GGACGGCGGC GTGCAGCTCG CCGACCACTA CCAGCAGAAC 661 ACCCCCATCG GCGACGGCCC CGTGCTGCTG CCCGACAACC ACTACCTGAG CTACCAGTCC 721 GCCCTGAGCA AAGACCCCAA CGAGAAGCGC GATCACATGG TCCTGCTGGA GTTCGTGACC 781 GCCGCCGGGA TCACTCTCGG CATGGACGAG CTGTACAAGT AAGAATTCAA GGCCTCTCGA 841 GCCTCTAGAG TTAACATCGA GGGATCAAGC TTATCGATAA TCAACCTCTG GATTACAAAA 901 TTTGTGAAAG ATTGACTGGT ATTCTTAACT ATGTTGCTCC TTTTACGCTA TGTGGATACG 961 CTGCTTTAAT GCCTTTGTAT CATGCTATTG CTTCCCGTAT GGCTTTCATT TTCTCCTCCC 1021 TTGTATAAAT CCTGGTTTGC TGTCTCTTTT ATGAGGAGTT TGTGGGCCGT TTGTCAGCAA 1081 CGTGGCGTGT GTGCAACTGT GATTTGCCTG AACGCACCCC AACTGCTTTG GGGGCATTGC 1141 CCACCCACCA GGGTTCCAGC CTTCCC //
Primer: HIVgp_R1	RDB04383_A2Kmc.seq
>04383_04383_A2Km_HIVgp_R1_F01_16.ab1 1 CCAGCTCTAT TCCACTGCTC TTTTTTCTCT CTGCACCACT CTTCTCTTTG CCTTGGTGGG 61 TGCTACTCCT AATGGTTCAA TTTTTACTAC TTTATATTTA TATAATTCAC TTCTCCAATT 121 GTCCCTCATA TCTCCTCCTC CAGGTCTGAA GATCAGCGGC CGGCCGCTTG CTGTGCGGTG 181 GTCTTACTTT TGTTTTGCTC TTCCTCTATC TTGTCTAAAG CTTCCTTGGT GTCTTTTATC 241 TCTATCCTTT GATGCACACA ATAGAGGGTT GCTACTGTAT TATATAATGA TCTAAGTTCT 301 TCTGATCCTG TCTGAAGGGA TGGTTGTAGC TGTCCCAGTA TTTGTCTACA GCCTTCTGAT 361 GTTTCTAACA GGCCAGGATT AACTGCGAAT CGTTCTAGCT CCCTGCTTGC CCATACTATA 421 TGTTTTAATT TATATTTTTT CTTTCCCCCT GGCCTTAACC GAATTTTTTC CCATCGCGAT 481 CTAATTCTCC CCCGCTTAAT ACTGACGCTC TCGCACCCAT CTCTCTCCTT CTAGCCTCCG 541 CTAGTCAAAA TTTTTGGCGT ACTCACCAGT CGCCGCCCCT CGCCTCTTGC CGTGCGCGCT 601 TCAGCAAGCC GAGTCCTGCG TCGAGAGAGC TCCTCTGGTT TCCCTTTCGC TTTCAAGTCC 661 CTGTTCGGGC GCCACTGCTA GAGATTTTCC ACACTGACTA AAAGGGTCTG AGGGATCTCT 721 AGTTACCAGA GTCACACAAC AGACGGGCAC ACACTACTTG AAGCACTCAA GGCAAGCTTT 781 ATTGAGGCTT AAGCAGTGGG TTCCCTAGTT AGCCAGAGAG CTCCCAGGCT CAGATCTGGT 841 CTAACCAGAG AGACCCAGTA CAGGCAAAAC GCGCTGCTTA TATAGACCTC CCACCGTACA 901 CGCCTACCGC CCATTTGCGT CAATGGGGGC GGAGTTGTTA CGACATTTTG GAAAGTCCCG 961 TTGATTTTGG TGCCAAAACA AACTCCCATT GACGTCAATG GGGTGGAGAC TTGGAAAATC 1021 CCCGTGAGTC AAACCGCTAT CCACGCCCAT TGATGTACTG CCCAAACGCA TCACCATGGT 1081 AATAGCGATG ACTAATACGT AGATGTACTG CCAAGTAGGA AAGTTCCATT CGTTCAATGT 1141 ACTGGGCATA TGCAGGCGGG TCCAATTTTA CCCGGTCCAT TGGAAGCG //
Primer: BGH_rev	RDB04383_A2Kmd.seq
>04383_04383_A2Km_BGHrev_G01_19.ab1 1 GTTTCGGACT GCTAGAGATT TTCCACACTG ACTAAAAGGG TCTGAGGGAT CTCTAGTTAC 61 CAGAGTCACA CAACAGACGG GCACACACTA CTTGAAGCAC TCAAGGCAAG CTTTATTGAG 121 GCTTAAGCAG TGGGTTCCCT AGTTAGCCAG AGAGCTCCCA GGCTCAGATC TGGTCTAACC 181 AGAGAGACCC AGTACAGTCC GGATGCAGCT CTCGGGCCAT GTGATGAAAT GCTAGGCGGC 241 TGTCAAACCT CCACTCTAAT ACTTCTCTCT CCGGGTCATC CATCCCATGC AGGCTCACAG 301 GGTGTAACAA GCGGGTGTTC TCTCCTTCAT TGGCTTCTTC TACCTTCTCT TGCTCAACTG 361 GTACTAGCTT GTAGCACCAT CCAAAGGTCA GTGGATATCT GATCCCTGGC CCTGGTGTGT 421 AGTTCTGCCA ATCAGGGAAG TAGCCTTGTG TGTGGTAGAT CCACAGATCA AGGATATCTT 481 GTCTTCGTTG GGAGTGAATT AGCCCTTCCA GTCCCCCCTT TTCTTTTAAA AAGTGGCTAA 541 GATCTACAGC TGCCTTGTAA GTCATTGGTC TTAAAGGTAC CTGAGGTGTG ACTGGAAAAC 601 CCACCTCCTC CTCCTCTTGT GCTTCTAGCC AGGCACAATC AGCATTGGTA GCTGCTGTAT 661 TGCTACTTGT GATTGCTCCA TGTTTTTCTA GGTCTCGACG GTATCGATGC GGGGAGGCGG 721 CCCAAAGGGA GATCCGACTC GTCTGAGGGC GAAGGCGAAG ACGCGGAAGA GGCCGCAGAG 781 CCGGCAGCAG GCCGCGGGAA GGAAGGTCCG CTGGATTGAG GGCCGAAGGG ACGTAGCAGA 841 AGGACGTCCC GCGCAGAATC CAGGTGGCAA CACAGGCGAG CAGCCATGGA AAGGACGTCA 901 GCTTCCCCGA CAACACCACG GAATTGTCAG TGCCCAACAG CCGAGCCCCT GTCCAGCAGC 961 GGGCAAAGGC AGGCGGCGAT GAGTTCCGCC GTGGCAATAC GGGAGGGGGA AAGCGAAAGT 1021 CCCGGGAAGG AGCTGACAGG TGGTGGCAAT GCCCCAACCC AGTGGGGGGT TGCGTCAGCA 1081 AACACAGTGC ACACCACGCA CGTTGCCTGA CACGGGCCAC ACTTCTCATA AGAGACAGGC 1141 CATCAGATTT TATACAAGGA AGGGAAGAAA ATTGAAAAGC CCAATATACC CG //
Primer: SV40pro_F	RDB04383_A2Kme.seq
>04383_04383_A2Km_SV40pro_F_H01_22.ab1 1 CCCTGTCCCT GGCATTCAGA GTAGTGAGGA GGCTTTTTTG GAGGCCTAGG CTTTTGCAAA 61 AAGCTCCCGG GAGCTTGTAT ATCCATTTTC GGATCTGATC AGCACGTGTT GACAATTAAT 121 CATCGGCATA GTATATCGGC ATAGTATAAT ACGACAAGGT GAGGAACTAA ACCATGGCCA 181 AGTTGACCAG TGCCGTTCCG GTGCTCACCG CGCGCGACGT CGCCGGAGCG GTCGAGTTCT 241 GGACCGACCG GCTCGGGTTC TCCCGGGACT TCGTGGAGGA CGACTTCGCC GGTGTGGTCC 301 GGGACGACGT GACCCTGTTC ATCAGCGCGG TCCAGGACCA GGTGGTGCCG GACAACACCC 361 TGGCCTGGGT GTGGGTGCGC GGCCTGGACG AGCTGTACGC CGAGTGGTCG GAGGTCGTGT 421 CCACGAACTT CCGGGACGCC TCCGGGCCGG CCATGACCGA GATCGGCGAG CAGCCGTGGG 481 GGCGGGAGTT CGCCCTGCGC GACCCGGCCG GCAACTGCGT GCACTTCGTG GCCGAGGAGC 541 AGGACTGACA CGTGCTACGA GATTTCGATT CCACCGCCGC CTTCTATGAA AGGTTGGGCT 601 TCGGAATCGT TTTCCGGGAC GCCGGCTGGA TGATCCTCCA GCGCGGGGAT CTCATGCTGG 661 AGTTCTTCGC CCACCCCAAC TTGTTTATTG CAGCTTATAA TGGTTACAAA TAAAGCAATA 721 GCATCACAAA TTTCACAAAT AAAGCATTTT TTTCACTGCA TTCTAGTTGT GGTTTGTCCA 781 AACTCATCAA TGTATCTTAT CATGTCTGTA TACCGTCGAC CTCTAGCTAG AGCTTGGCGT 841 AATCATGGTC ATAGCTGTTT CCTGTGTGAA ATTGTTATCC GCTCACAATT CCACACAACA 901 TACGAGCCGG AAGCATAAAG TGTAAAGCCT GGGGTGCCTA AATGAGTGAG CTAACTCACA 961 TTAATTGCGT TGCGCTCACT GCCCGCTTTC CAGTCGGGAA ACCTGTCGTG CCAGCTGCAT 1021 TAATGAATCG GCCCAACGCG CGGGGAGAGG CGGTTTTGCG TATTGGCGCT CTTCCGCTTT 1081 CTCGCTCACT GACTCGCTGC GCTCGCTCGC TCCGGCTGCC GGCGAGCCGG TAATCAGCTC 1141 ACTTCAAAGG CCGGTAAAAT TACCGGCTAA C //

Please visit Sequencing and PCR primers for primer information.

References

reference	Ikemoto, M., Autologous transplantation of SM/C-2.6(+) satellite cells transduced with micro-dystrophin CS1 cDNA by lentiviral vector into mdx mice. Mo.l Ther. 15 (12): 2178-2185 (2007). PMID 17726457.
user report	Kikuchi, J., Myeloma Cells are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex which Senses Lipopolysaccharide. Cancer Res. 78 (7): 1766-1778 (2018). PMID 29363546.
user report	Osada, N., Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells. Oncotarget 9 (5): 6450-6462 (2018). PMID 29464084.
user report	Uenaka, T., In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson's disease. Hum. Mol. Genet. 27 (22): 3974-3985 (2018). PMID 30137437.
user report	Tanaka, M., Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease. J. Clin. Invest. 127 (4): 1438-1450 (2017). PMID 28263187.
user report	Su, Z., Neurocan, an extracellular chondroitin sulfate proteoglycan, stimulates neuroblastoma cells to promote malignant phenotypes. Oncotarget 8 (63): 106296-106310 (2017). PMID 29290949.
user report	Sasamoto, Y., PAX6 Isoforms, along with Reprogramming Factors, Differentially Regulate the Induction of Cornea-specific Genes. Sci. Rep. 6: 20807, 2016. PMID 26899008.
user report	Lu, F., Downregulation of CREB Promotes Cell Proliferation by Mediating G1/S Phase Transition in Hodgkin Lymphoma. Oncol. Res. 24 (3): 171-179 (2016). PMID 27458098.
user report	Hikita, A., Analyses of bone modeling and remodeling using in vitro reconstitution system with two-photon microscopy. Bone 76: 5-17 (2015). PMID 25771421.
user report	Minamino, M., Esco1 Acetylates Cohesin via a Mechanism Different from That of Esco2. Curr. Biol. 25 (13): 1694-1706 (2015). PMID 26051894.
user report	Kikuchi, J., The novel orally active proteasome inhibitor K-7174 exerts anti-myeloma activity in vitro and in vivo by down-regulating the expression of class I histone deacetylases. J. Biol. Chem., 288 (35): 25593-25602 (2013). PMID 23878197.
user report	Matsushita, M., Meclozine Facilitates Proliferation and Differentiation of Chondrocytes by Attenuating Abnormally Activated FGFR3 Signaling in Achondroplasia. PLoS One, 8 (12): e81569 (2013). PMID 24324705.
user report	Kikuchi J., Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma. Blood., 116, 406-417 (2010). PMID 20351311.

2019.04.18

GNP_filter3_RDBDEP_html_190418.pl